Synthetic Biologics to Present at the 2016 BIO CEO & Investor Conference
ROCKVILLE, Md., Feb. 3, 2016 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that Jeffrey Riley, CEO, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 8, 2016, at 8:30 a.m. (ET) at the Waldorf Astoria (Conrad room) in New York.
A live webcast of Synthetic Biologics' presentation may be accessed by logging onto the internet at https://www.veracast.com/webcasts/bio/ceoinvestor2016/83103495204.cfm. After the presentation, a replay will be archived and accessible for 90 days at the same website.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company's lead candidates in Phase 2 development include: (1) SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). In collaboration with Intrexon Corporation (NYSE: XON), the Company is developing a preclinical stage monoclonal antibody for the prevention and treatment of Pertussis, and discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-present-at-the-2016-bio-ceo--investor-conference-300214062.html
SOURCE Synthetic Biologics, Inc.
Released February 3, 2016